Notably, although the median baseline PTH level of 1262 pg/mL was observed in this study, the overall proportion of patients who achieved a reduction in PTH of at least 30% from baseline was comparable to results reported in two previous randomized clinical studies, with median baseline PTH levels of approximately 600 to 850 pg/mL11,24 but lower than the reported 90.3% among patients randomized to cinacalcet in a phase 3 trial among Japanese HD patients, with median baseline PTH levels of 606.5 pg/mL10. The gene discussed is PTH; the disease is Huntington disease.